BCL2 and colorectal cancer: AXT was proposed to have anti-cancer properties by upregulating proapoptotic proteins (Bax/Bad and PARP) and downregulating anti-apoptotic proteins (Bcl2, p-Bad, and survivin) in colorectal cancer, melanoma, and gastric carcinoma cell lines [21].